Prophylaxis versus preemptive protocols for CMV: Do they impact graft survival?

American Journal of Transplantation

Volumn 8, Issue 5, 2008, Pages 913-914

  Miller, G G ^a   Kaplan, B ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; UNCLASSIFIED DRUG; VALGANCYCLOVIR;

ANTIVIRAL THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; EDITORIAL; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INFECTION PREVENTION; KIDNEY GRAFT; MORTALITY; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 42149185087     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02181.x     Document Type: Editorial

References (10)

1. Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007 21 : 149 158.
2. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomized controlled trials. Lancet 2005 365 : 2105 2115.
3. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005 143 : 870 880.
4. Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006 81 : 139 145.
5. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006 6 : 2134 2143.
6. Jung C, Engelmann E, Borner K, Offermann G. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001 33 : 3621 3623.
7. Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004 66 : 329 337.
8. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004 4 : 928 936.
9. Singh N, Wannstedt C, Keyes L et al. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005 79 : 1428 1434.
10. Kliem V, Fricke L, Wollbrink T et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2007.